Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

CROSSJECT

Olivier Giré

Didier Morin

Patrick ALEXANDRE

Svensson Marianne

This department is responsible for ensuring compliance with validation and qualification standards in processes and products.

Quality Assurance

This department focuses on the design, development, and testing of equipment and engineering solutions.

Engineering Development

This department manages employee relations, recruitment, training, and organizational development.

Human Resources

This department oversees project planning and execution to enhance industrial performance.

Project Management

This department is responsible for ensuring that products meet established quality standards and comply with regulations before release.

Quality Control

This department focuses on the advancement and optimization of analytical methodologies and formulations.

CROSSJECT

Org chart

Teams

Quality Assurance

Engineering Development

Human Resources

Project Management

Quality Control

Analytical Development

Offices

CROSSJECT

Org chart

Teams

Quality Assurance

Engineering Development

Human Resources

Project Management

Quality Control

Analytical Development

Offices

Related companies